For the first time, the CiQUS team has synthesized a bioactive compound — dimestrol, a non-steroidal estrogen used in hormone replacement therapy — directly from methane. This feat marks a rupture in the pharmaceutical industry: transforming abundant natural gas into complex molecules without passing through traditional petrochemical circuits.
By designing an innovative catalyst based on iron activated by LED, researchers have managed to activate recalcitrant molecules like methane and transform them into complex compounds, opening the way to less polluting and more economical pharmaceutical chemistry. It remains to be proven that this innovation can rival the giants of petrochemistry.
The Essentials
- First global success: direct synthesis of dimestrol (hormonal medication) from methane via an iron-LED catalyst
- CiQUS demonstrates that methane can become a simple, abundant, and low-cost raw material for complex high-value molecules
- The system functions under relatively mild conditions, which could facilitate scaling up
- The pharmaceutical sector drives the growth of the methanesulfonic acid market at a rate of 4.7% per year
Methane Defies Pharmaceutical Petrochemistry
Natural gas, due to its abundance and low cost, represents a major supply source for the petrochemical and chemical industry. Petrochemical products, derived from petroleum resources such as ethane, naphtha, and natural gas, traditionally use resources from the petroleum sector, notably natural gas, condensates, and naphtha.
Natural gas constitutes one of the most abundant energy resources on the planet. It is composed mainly of methane, with ethane and propane. Today, it is primarily burned for heating and electricity, a process that releases greenhouse gases.
One of the main challenges lies in the initial activation of the methane molecule. This has led to the development of several different approaches for using methane, some more developed than others. The direct conversion of methane into valuable compounds opens the way to energy and resource-efficient processes that present significant advantages over the multi-stage processing of natural gas. For example, the oxidative condensation of methane into ethylene makes it possible to replace rare petroleum raw materials with natural gas in the production of this most important semi-product of petrochemical chemistry.
An Iron Catalyst Revolutionizes Methane Activation
The team’s strategy focuses on a reaction called allylation, which consists of attaching a small chemical “handle” (an allyl group) to the gas molecule. This handle serves as a versatile anchor, allowing subsequent steps to build a wide range of final products — from active pharmaceutical ingredients to everyday chemicals.
The main obstacle was the catalytic system’s tendency to produce undesirable chlorination by-products, derailing the process. To overcome this obstacle, the team designed a custom supramolecular catalyst.
The heart of this breakthrough lies in the design of a catalyst based on a tetrachloroferrate anion stabilized by collidinium cations, which effectively modulates the reactivity of radical species generated in the reaction medium, explains Professor Martín Fañanás of CiQUS.
The formation of a complex network of hydrogen bonds around the iron atom maintains the photocatalytic reactivity necessary to activate the alkane, while simultaneously suppressing the catalyst’s tendency to undergo competing chlorination reactions. This creates an optimal environment for the selective allylation reaction to proceed. The system uses iron instead of precious metals and operates under mild conditions powered by LED light.
The Pharmaceutical Industry Adopts Sustainable Alternatives
Pharmaceutical synthesis remains the main driver of the methanesulfonic acid market, contributing approximately 41% of total application demand. Over 58% of newly developed active pharmaceutical ingredients use strong organic acids in the formation of intermediates.
The increased prevalence of chronic diseases and the resulting increase in global pharmaceutical demand have a direct positive impact on the methanesulfonic acid market. As pharmaceutical companies expand their production capacities to meet this growing demand, the need for effective and reliable catalysts like methanesulfonic acid increases.
Methanesulfonic acid has replaced nitric, fluoroboric, and perchloric acids in 30 to 40% of plating facilities and 25 to 35% of pharmaceutical synthesis routes due to its reduced corrosiveness and superior safety. Plating yields improve by 5 to 20% and waste disposal costs decrease by 10 to 40% with the substitution.
Global concern for a sustainable future as well as the advancement of green products with biotechnological pathways have strengthened the use of bio-catalysis, also called green catalyst, in industrial fields. Developments in green chemistry are intrinsically linked mainly to bio-catalyst due to its key synthesis from renewable sources.
The Challenges of Industrial Scale-Up
Methane remains abundant and inexpensive, but its climate impact is severe. Transforming it into stable chemical products could reduce emissions and support a circular chemical economy.
The difficulties of catalyst deactivation, a limited field of application for reusability, a restricted substrate scope, and barriers to economic scalability continue to hinder industrial adoption in this field.
One of the most common chemical processing chains in the United States distills ethane from natural gas (a chemical raw material), which is then “cracked” into ethylene (a primary chemical) and eventually transformed into plastics and other materials. The production of primary chemicals — notably ethylene, propylene, benzene, toluene, xylene, ammonia, and methanol — emits the most greenhouse gases along the chemical supply chain. These “process emissions” come from the combustion of additional fossil fuels to generate the high temperatures (up to 1,000 degrees C) necessary to transform fossil fuels into primary chemicals.
As the world transitions toward cleaner energy, the petrochemical sector stands out as a long-term driver of demand for natural gas — particularly for its non-combustible use as a raw material. Unlike electricity generation, where renewable energies are rapidly replacing fossil fuels, the role of chemical transformation of hydrocarbons remains irreplaceable in many cases.
Green Chemistry Redraws Supply Circuits
The industry, from small businesses to large corporations, has already taken strategic measures toward sustainability by adopting the principles of green chemistry. The development of less hazardous commercial processes and products, the shift from inefficient chemical pathways toward bio-based synthesis, and the replacement of petroleum-based raw materials with renewable starting materials are just some examples of the major decisions made that will ultimately have vast consequences for global chemical markets.
Their extreme stability and low reactivity posed a formidable challenge, limiting their use as sustainable raw materials for the chemical industry. The ability to convert natural gas into versatile chemical intermediates opens new possibilities for the industry, laying the groundwork for progressively replacing petrochemical sources with more sustainable alternatives.
The implementation of a process to assist downstream industry with the use of CO2 and provide a low-carbon hydrogen supply is highly desirable. This represents a paradigm shift where sustainability is the main product and chemicals based on fossil fuels are a carbon sink with significant market value. The sustainability value will be highest for methane raw materials and will also offer one of the most efficient uses of renewable electricity.
This breakthrough by CiQUS transforms a challenge that has existed for several decades into a business opportunity. The CiQUS team continues to test new molecules and refine catalyst designs. They argue that the method offers a model for cleaner industrial chemistry. It now remains to be proven that this green chemistry can compete economically with established petrochemical giants and convince a traditionally conservative pharmaceutical industry to adopt this new synthesis pathway.
Sources: